The FDA has approved Novo Nordisk’s Ozempic—once-weekly semaglutide—for an expanded indication of CV risk reduction in people with type 2 diabetes and established heart disease.

A cross-structural analysis published in Mayo Clinic Proceedings this January independently links diabetes to the development of heart failure, suggesting diabetic cardiomyopathy is a real—and growing—issue in the U.S.

One Minneapolis cardiologist is concerned that people following the trendy Keto diet aren’t worrying enough about their fat intake.

Pharmaceutical company Novartis has partnered with the U.K.’s National Health Service to study inclisiran, an investigational cholesterol-lowering drug that experts project could save 30,000 lives over the next decade.

U.K.-based drug giant AstraZeneca announced Jan. 13 it would be halting its Phase III trial of Epanova, a medication comprised of omega-3 carboxylic acids, early due to disappointing data.

The future of diabetes diagnosis and management could lie in a “smart” LED contact lens, a study published in Nature Reviews Materials suggests.

Research led by a team at the University of Kentucky and funded by the American Heart Association and National Institutes of Health has uncovered a new biomarker for cardiovascular disease: an apolipoprotein/antibody combo.

Switching to a healthier diet could save Americans more than $300 annually and could cut U.S. healthcare costs by $50 billion, a new study suggests.

The American Heart Association on Dec. 13 announced that it would be awarding more than $14 million in research grants to advance its new Strategically Focused Research Network on Cardiometabolic Health and Type 2 Diabetes.

Atrial fibrillation patients who are obese are less likely to respond to sodium channel blockers than their normal-weight peers, according to a new study.

A study published in JACC suggests that, when combined with high-intensity statin therapy, evolocumab can be an effective tool for lowering LDL-cholesterol in patients who have experienced an acute coronary syndrome.

The FDA is testing metformin, a popular drug used to treat type 2 diabetes, for carcinogenic impurities.